Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review

被引:43
作者
Li, Xin [1 ,2 ]
Song, Yongcheng [1 ,2 ]
机构
[1] Baylor Coll Med, Dept Pharmacol & Chem Biol, 1 Baylor Plaza, Houston, TX 77030 USA
[2] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, 1 Baylor Plaza, Houston, TX 77030 USA
关键词
SARS-CoV-2; Main protease; Small-molecule inhibitor; Drug discovery; RESPIRATORY SYNDROME CORONAVIRUS; STRUCTURE-BASED DESIGN; SMALL-MOLECULE INHIBITORS; 3CL PROTEASE; BIOLOGICAL EVALUATION; M-PRO; COVALENT INHIBITORS; SUBSTRATE-SPECIFICITY; NONCOVALENT INHIBITORS; IDENTIFIES INHIBITORS;
D O I
10.1016/j.ejmech.2023.115772
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003 infected-8000 people in 26 countries with 800 deaths, which was soon contained and eradicated by syndromic surveillance and enhanced quarantine. A closely related coronavirus SARS-CoV-2, the causative agent of COVID-19 identified in 2019, has been dramatically more contagious and catastrophic. It has infected and caused various flu-like symptoms of billions of people in >200 countries, including >6 million people died of or with the virus. Despite the availability of several vaccines and antiviral drugs against SARS-CoV-2, finding new therapeutics is needed because of viral evolution and a possible emerging coronavirus in the future. The main protease (Mpro) of these coronaviruses plays important roles in their life cycle and is essential for the viral replication. This article represents a comprehensive review of the function, structure and inhibition of SARS-CoV and-CoV-2 Mpro, including structure-activity relationships, protein-inhibitor interactions and clinical trial status.
引用
收藏
页数:22
相关论文
共 326 条
  • [1] Repurposing of Some Natural Product Isolates as SARS-COV-2 Main Protease Inhibitors via In Vitro Cell Free and Cell-Based Antiviral Assessments and Molecular Modeling Approaches
    Abdallah, Hossam M.
    El-Halawany, Ali M.
    Sirwi, Alaa
    El-Araby, Amr M.
    Mohamed, Gamal A.
    Ibrahim, Sabrin R. M.
    Koshak, Abdulrahman E.
    Asfour, Hani Z.
    Awan, Zuhier A.
    A. Elfaky, Mahmoud
    [J]. PHARMACEUTICALS, 2021, 14 (03)
  • [2] Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening
    Abian, Olga
    Ortega-Alarcon, David
    Jimenez-Alesanco, Ana
    Ceballos-Laita, Laura
    Vega, Sonia
    Reyburn, Hugh T.
    Rizzuti, Bruno
    Velazquez-Campoy, Adrian
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2020, 164 : 1693 - 1703
  • [3] Ahmed M., 2021, Identification of Atovaquone and Mebendazole as Repurposed Drugs with Antiviral Activity against SARS-CoV-2 (Version 6)
  • [4] Synthesis and Evaluation of Benzoquinolinone Derivatives as SARS-CoV 3CL Protease Inhibitors
    Ahn, Tae-Young
    Kuo, Chih-Jung
    Liu, Hun-Ge
    Ha, Deok-Chan
    Liang, Po-Huang
    Jung, Young-Sik
    [J]. BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2010, 31 (01): : 87 - 91
  • [5] Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant
    Akaji, Kenichi
    Konno, Hiroyuki
    Onozuka, Mari
    Makino, Ayumi
    Saito, Hiroyuki
    Nosaka, Kazuto
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (21) : 9400 - 9408
  • [6] Structure-Based Design, Synthesis, and Evaluation of Peptide-Mimetic SARS 3CL Protease Inhibitors
    Akaji, Kenichi
    Konno, Hiroyuki
    Mitsui, Hironori
    Teruya, Kenta
    Shimamoto, Yasuhiro
    Hattori, Yasunao
    Ozaki, Takeshi
    Kusunoki, Masami
    Sanjoh, Akira
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (23) : 7962 - 7973
  • [7] An efficient method for the synthesis of peptide aldehyde libraries employed in the discovery of reversible SARS coronavirus main protease (SARS-CoV Mpro) inhibitors
    Al-Gharabli, Samer I.
    Shah, Syed T. Ali
    Weik, Steffen
    Schmidt, Marco F.
    Mesters, Jeroen R.
    Kuhn, Daniel
    Klebe, Gerhard
    Hilgenfeld, Rolf
    Rademann, Joerg
    [J]. CHEMBIOCHEM, 2006, 7 (07) : 1048 - 1055
  • [8] Neoechinulin A as a Promising SARS-CoV-2 Mpro Inhibitor: In Vitro and In Silico Study Showing the Ability of Simulations in Discerning Active from Inactive Enzyme Inhibitors
    Alhadrami, Hani A.
    Burgio, Gaia
    Thissera, Bathini
    Orfali, Raha
    Jiffri, Suzan E.
    Yaseen, Mohammed
    Sayed, Ahmed M.
    Rateb, Mostafa E.
    [J]. MARINE DRUGS, 2022, 20 (03)
  • [9] Scaffold Hopping of α-Rubromycin Enables Direct Access to FDA-Approved Cromoglicic Acid as a SARS-CoV-2 MPro Inhibitor
    Alhadrami, Hani A.
    Sayed, Ahmed M.
    Al-Khatabi, Heba
    Alhakamy, Nabil A.
    Rateb, Mostafa E.
    [J]. PHARMACEUTICALS, 2021, 14 (06)
  • [10] Cnicin as an Anti-SARS-CoV-2: An Integrated In Silico and In Vitro Approach for the Rapid Identification of Potential COVID-19 Therapeutics
    Alhadrami, Hani A.
    Sayed, Ahmed M.
    Hassan, Hossam M.
    Youssif, Khayrya A.
    Gaber, Yasser
    Moatasim, Yassmin
    Kutkat, Omnia
    Mostafa, Ahmed
    Ali, Mohamed Ahmed
    Rateb, Mostafa E.
    Abdelmohsen, Usama Ramadan
    Gamaleldin, Noha M.
    [J]. ANTIBIOTICS-BASEL, 2021, 10 (05):